RxDoctor Payments Data

Alison Carlew, PA

Physician Assistant · Knoxville, TNNPI 1619567278

Payments from drug & device makers

$3,565in general payments, 2019–2025

Across 135 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$618
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$453
  • Teva Pharmaceuticals USA, Inc.$447
  • Otsuka America Pharmaceutical, Inc.$437
  • Genentech USA, Inc.$362
  • Sunovion Pharmaceuticals Inc.$208
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,565 in reported general payments places this provider in the 85th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$21,676
Medicare patients
27
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl20$31,372
VyvanseLisdexamfetamine Dimesylate11$4,103
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$2,920
Bupropion XlBupropion Hcl24$1,395
Duloxetine Hcl33$869
Quetiapine Fumarate22$387
Gabapentin13$350
Buspirone Hcl18$309
Trazodone Hcl16$258
Sertraline Hcl13$252
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$182
Clonazepam26$110
Lamotrigine11$99
Citalopram HbrCitalopram Hydrobromide12$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$618$31,37220 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$152$4,10311 claims
Almatica Pharma LLCSertraline Hcl$25$25213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →